The Panther Fusion SARS-CoV-2 Assay from Hologic Inc. - fully automated PCR for high-throughput labs

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-22, 17:28. Details in the imprint.

Panther Fusion SARS-CoV-2 Assay from Hologic hums quietly inside a hospital lab, drawing sealed tubes from a rack and sliding them into the Panther analyzer while the operator just watches the touchscreen. No pipetting, no plate juggling, just samples in and results out.

What the assay actually does

The Panther Fusion SARS-CoV-2 Assay is a real-time RT-PCR test that runs on the fully automated Panther and Panther Fusion systems, detecting SARS-CoV-2 RNA from upper respiratory specimens in one integrated workflow. Hologic positions it for high-throughput clinical laboratories that need reliable molecular results around the clock. The official product page describes the assay design and target genes.

Once samples are loaded, the Panther platform performs extraction, amplification and detection automatically, with lab staff mainly interacting via the touchscreen interface to review runs and release results. That hands-off approach reduces manual steps compared with many benchtop PCR workflows and can ease staffing pressure in busy virology labs.

Throughput and random access

Hologic quotes a throughput of up to about 1,150 results per 24 hours on a single Panther instrument when run as a high-volume SARS-CoV-2 assay, because the system processes samples in continuous random access instead of fixed batches. A company CE-mark press release details these capacity claims.

For a lab technologist like Dr. Maria Keller in a mid-sized European reference lab, that means trays of swabs can be loaded as they arrive without waiting to fill a plate. The machine pulls one tube after another with a quiet click of the robotic arm, while completed results start appearing on screen roughly three hours after first loading.

Regulatory status and accuracy

The Panther Fusion SARS-CoV-2 Assay initially received CE-IVD marking in Europe in early 2020 and later obtained Emergency Use Authorization from the US FDA as a high-throughput molecular diagnostic for SARS-CoV-2. The FDA EUA summary outlines performance data and intended use.

Validation studies in the EUA documentation report clinical sensitivity and specificity figures in the high 90 percent range when compared with reference RT-PCR methods, depending on sample type and comparator assay. That places the Fusion assay in the expected performance corridor for modern laboratory PCR tests used for COVID-19 diagnosis.

How it fits into the Panther ecosystem

For Hologic, the Fusion SARS-CoV-2 Assay plugs into an existing ecosystem of Panther and Panther Fusion assays for respiratory, sexually transmitted and other infectious diseases. Lab managers can mix SARS-CoV-2 testing with, for example, multiplex respiratory panels or CT/NG assays on the same instrument, subject to capacity.

This flexibility matters for labs that entered the pandemic with Panther already installed for women’s health testing. Tom West, President of Hologic’s Diagnostic Solutions business, has repeatedly highlighted the recurring revenue stream from assay cartridges and the advantage of leveraging the installed Panther base when launching new molecular tests.

Workflow and everyday handling

In day-to-day use, technicians load barcoded sample tubes and reagent cartridges into the Panther’s drawers, then let the system queue and process runs automatically. The sealed, walkaway design keeps aerosols contained, which can be reassuring during respiratory virus season when racks of swabs arrive every hour.

The assay uses proprietary Aptima reagents compatible with the Panther’s sample-to-result workflow, so labs familiar with Hologic’s other tests see similar cartridge handling and software screens. That consistency helps cross-train staff, especially when teams are stretched and new hires are learning on the job.

Pricing, availability and target users

Hologic sells the Panther Fusion SARS-CoV-2 Assay mainly to hospital networks, national reference laboratories and large private lab chains, structured as reagent kits and per-test consumables tied to installed Panther instruments. Exact pricing varies by contract, volume commitments and region, and is usually part of broader molecular diagnostics agreements.

In Europe and many other CE-mark regions the assay is available as a routine IVD product, while in the United States it remains aligned with FDA EUA conditions that have been in place for COVID-19 molecular diagnostics. For smaller labs without Panther systems, the barrier is less the assay itself and more the capital decision to bring a Panther analyzer on site.

Company context and stock note

Hologic positions its Panther and Fusion assays, including SARS-CoV-2, as growth drivers within its Diagnostics segment alongside women’s health and virology panels. For investors, that means recurring consumables revenue layered on a global installed base of Panther instruments in more than 70 countries.

Hologic shares (ISIN US4364401012) trade on the NASDAQ in US dollars, with the diagnostics business and its molecular platforms seen as key contributors to the company’s medium-term earnings profile.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.